Skip to main content

Table 2 Methylation frequencies in the analyzed sample cohorts assessed by quantitative methylation-specific polymerase chain reaction

From: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

Samples/Biomarkers

CNRIP1

FBN1

INA

SNCA

MAL

SPG20 §

Biomarker panel

Colon Cancer Cell Lines*

20/20 (100%)

18/20 (90%)

19/20 (95%)

18/20 (90%)

19/20 (95%)

20/20 (100%)

20/20 (100%)

Adenomas Test Set

54/60 (90%)

41/60 (68%)

25/60 (42%)

33/60 (55%)

51/60 (85%)

45/60 (75%)

54/60 (90%)

Adenomas Validation Set

47/51 (92%)

36/51 (71%)

14/51 (27%)

26/51 (51%)

42/51 (82%)

42/51 (82%)

49/51 (96%)

Adenomas Combined (Test and Validation Sets)

101/111 (91%)

77/111 (69%)

39/111 (35%)

59/111 (53%)

93/111 (84%)

87/111 (78%)

103/111 (93%)

CRC Test Set

73/74 (99%)

60/74 (81%)

49/74 (66%)

54/74 (73%)

68/74 (92%)

67/74 (91%)

73/74 (99%)

CRC Validation Set

96/105 (91%)

82/105 (78%)

68/105 (65%)

65/105 (62%)

94/105 (90%)

92/105 (88%)

95/105 (90%)

Normal Mucosa Matching CRC Validation Set

42/105 (40%)

2/105 (2%)

0/105 (0%)

0/105 (0%)

3/105 (3%)

0/105 (0%)

4/105 (4%)

CRCs Combined (Test and Validation Sets)

169/179 (94%)

142/179 (79%)

117/179 (65%)

119/179 (66%)

162/179 (91%)

159/179 (89%)

168/179 (94%)

Normal Mucosa Test Set

1/51 (2%)

1/51 (2%)

0/51 (0%)

0/51 (0%)

1/51 (2%)

1/51 (2%)

1/51 (2%)

Normal Mucosa Validation Set

5/59 (8%)

0/59 (0%)

0/59 (0%)

0/59 (0%)

1/59 (2%)

0/59 (0%)

1/59 (2%)

Normals Combined (Test and Validation Sets)

6/110 (5%)

1/110 (1%)

0/110 (0%)

0/110 (0%)

2/110 (2%)

1/110 (1%)

2/110 (2%)

  1. Abbreviation: CRC, colorectal cancer.
  2. * Colon Cancer Cell lines have been analyzed using qualitative methylation-specific PCR.
  3. § Previously published results [9].
  4. † Simultaneous methylation of two or more of the six markers provides a positive biomarker panel.